| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.3 | 4e-14 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.29 | 4e-12 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.25 | 1e-09 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-07 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.3 | 7e-07 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.2 | 8e-07 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.92 | 2e-06 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.17 | 3e-06 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-06 |